Objective: The primary aim of the present study was to evaluate the data and success of a smoking cessation clinic in a secondary state hospital. Secondarily, the study aimed to compare the cessation rates of patients using varenicline and bupropion. Methods: A total of 251 patients, admitted to our smoking cessation clinic were retrospectively evaluated. The smoking cessation clinic was run one day every week and included a 35-min presentation on smoking cessation and face-to-face interviews with every patient who attended the clinic. Monthly control visits were conducted, and after 2 years all the patients were asked about their smoking status via a phone call. Results: A total of 152 out of the 251 patients, namely those who were s...
Background: Smoking cessation therapies include counseling, psychological management and pharmacolog...
Introduction Smoking cessation clinic (SCC) was introduced into Singapore’s healthcare setting to co...
Varenicline (VAR) is a new selective α4β2 nicotine acetylcholine receptor partial agonist, available...
WOS: 000367541400006Smoking is still the most important cause of preventable diseases and premature ...
Objective: The purpose of this study was to quantify quit rates, determine factors predicting succes...
Background: Varenicline is an effective smoking cessation aid. However, smokers prescribed with vare...
Objectives: The aim of this study was to estimate the clinical efficacy of counseling combined with ...
Ba ckground: Hospitalization presents smokers with an opportunity to initiate smoking cessation. We ...
Introduction Long-term outcomes of smoking cessation treatments are crucial to optimize standards of...
BACKGROUND: Smoking is a major cause of morbidity in lower socioeconomic groups. In randomized trial...
OBJECTIVE: To evaluate the effectiveness of nicotine replacement therapy (NRT), bupropion, nortripty...
Aim and objective The aim of this study is to determine characteristics, smoking habits, therapy for...
Introduction: Our objectives were to assess the smoking cessation medication utilization patterns am...
Background: Smoking is the leading preventable cause of non-communicable disease worldwide. Therefor...
Background: “Smoking is the main avoidable cause of death around the world”. It’s prevalence is abou...
Background: Smoking cessation therapies include counseling, psychological management and pharmacolog...
Introduction Smoking cessation clinic (SCC) was introduced into Singapore’s healthcare setting to co...
Varenicline (VAR) is a new selective α4β2 nicotine acetylcholine receptor partial agonist, available...
WOS: 000367541400006Smoking is still the most important cause of preventable diseases and premature ...
Objective: The purpose of this study was to quantify quit rates, determine factors predicting succes...
Background: Varenicline is an effective smoking cessation aid. However, smokers prescribed with vare...
Objectives: The aim of this study was to estimate the clinical efficacy of counseling combined with ...
Ba ckground: Hospitalization presents smokers with an opportunity to initiate smoking cessation. We ...
Introduction Long-term outcomes of smoking cessation treatments are crucial to optimize standards of...
BACKGROUND: Smoking is a major cause of morbidity in lower socioeconomic groups. In randomized trial...
OBJECTIVE: To evaluate the effectiveness of nicotine replacement therapy (NRT), bupropion, nortripty...
Aim and objective The aim of this study is to determine characteristics, smoking habits, therapy for...
Introduction: Our objectives were to assess the smoking cessation medication utilization patterns am...
Background: Smoking is the leading preventable cause of non-communicable disease worldwide. Therefor...
Background: “Smoking is the main avoidable cause of death around the world”. It’s prevalence is abou...
Background: Smoking cessation therapies include counseling, psychological management and pharmacolog...
Introduction Smoking cessation clinic (SCC) was introduced into Singapore’s healthcare setting to co...
Varenicline (VAR) is a new selective α4β2 nicotine acetylcholine receptor partial agonist, available...